Trial Profile
COMPARISON OF THE PERFORMANCE OF SB2‐INFLIXIMAB WITH ORIGINATOR INFLIXIMAB IN THE MEASUREMENT OF CONCENTRATIONS IN SERUM
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Pharmacokinetics
- 16 Oct 2017 New trial record